Matching-Adjusted Indirect Comparisons Applied for Comparative Efficacy of Haematologic Cancer Drugs within Health Economic Analysis

Abstract

Matching-adjusted indirect comparisons (MAICs) have been used in health technology assessment submissions for a decade now. In theory, their specific utility could diminish the need for randomized-controlled trials (RCTs) and hence reduce the financial burden on manufacturers, as well as speed up patient access to novel drugs. However, despite the clarity in guidelines on methodological aspects, more research was needed and more time was required to fully understand their applicability in practice, their impact on health economic models, and the outlook of reimbursement agencies on them. Hence, the justification for the current thesis comes for it being researched and conducted during the "prime years" of MAICs.